No sensitive functional index is currently available to assess Cu status in healthy human populations. This study evaluated the effect of Cu supplementation on putative indices of Cu status in twelve women and twelve men, aged between 22 and 45 years, who participated in a double-blind placebo controlled crossover study. The study consisted of three 6-week supplementation regimens of 3 mg CuSO 4 , 3 mg Cu-glycine chelate and 6 mg Cu-glycine chelate, each separated by placebo periods of equal length. Women had signi®cantly higher caeruloplasmin oxidase activity (P , 0×001), caeruloplasmin protein concentration (P , 0×05), and serum diamine oxidase activity (P , 0×01) at baseline than men. Erythrocyte and leucocyte superoxide dismutase activity, leucocyte cytochrome c oxidase activity, and erythrocyte glutathione peroxidase activity did not respond to Cu supplementation. Platelet cytochrome c oxidase activity was signi®cantly higher (P , 0×01), after supplementation with 6 mg Cu-glycine chelate in the total group and in women but did not change in men. Caeruloplasmin oxidase activity was signi®cantly higher (P , 0×05), in men after supplementation with 3 mg Cu-glycine chelate, while caeruloplasmin protein concentration was signi®cantly lower in men after supplementation with 6 mg Cu-glycine chelate (P , 0×05). Serum diamine oxidase activity was signi®cantly higher after all supplementation regimens in the total group and in both men and women (P , 0×01). These results indicate that serum diamine oxidase activity is sensitive to changes in dietary Cu intakes and may also have the potential to evaluate changes in Cu status in healthy adult human subjects.
Cu has long been established as an essential micronutrient for health in both animals and humans. Clinically de®ned Cu de®ciency in humans, however, remains rare and has only been described in a small number of patients (Danks, 1988) . Severe Cu de®ciency, as diagnosed by a marked depression in circulating Cu and caeruloplasmin concentrations, is accompanied by anaemia and neurological, arterial and myocardial problems (Solomons, 1979; Turnlund, 1994) . Sub-optimal Cu status, however, may be present within populations and remain undetected as it is not associated with any overt clinical symptoms (Milne, 1994) , and no suitable, sensitive biochemical index of Cu status is currently available (Olivares & Uauy, 1996) .
The commonly used putative methods of Cu status assessment, serum and plasma Cu protein concentrations and caeruloplasmin oxidase activity, suffer from inherent problems in their interpretation. Serum or plasma Cu concentrations rise in conditions of stress. Caeruloplasmin is an acute-phase protein and concentrations are increased during in¯ammation, in smokers and in women using oral contraceptives and hormone replacement therapy (DiSilvestro, 1990; Fisher et al. 1990; Johnson et al. 1992) .
Erythrocyte superoxide dismutase (SOD) activity is cited as an alternative, functional means of assessing Cu status, but may not be sensitive to supplementation and to small changes in Cu status (Turnlund et al. 1990) . Moreover, erythrocyte SOD activity displays a high intra-individual variation (Gallagher et al. 1989) , and may be affected by conditions other than Cu status (DiSilvestro, 1988; Nielsen et al. 1990 ). Other Cu-metalloenzymes, such as platelet cytochrome c oxidase (CCO) activity and serum peptidylglycine a-amidating monooxygenase activity, have also been proposed as alternative, sensitive indices of Cu status Milne & Forrest, 1996; Prohaska, 1997) . Erythrocyte glutathione peroxidase (GPX), although not a Cu-dependent enzyme, appears to have lower activity during Cu depletion and has been suggested as an alternative to traditional indices of Cu status (Milne & Forrest, 1996) .
Another Cu-metalloenzyme, which has shown promise as a functional index of Cu status in human subjects , is diamine oxidase (DAO). The latter enzyme is responsible for the oxidative deamination of diamines, such as putrescine and cadaverine, and histamine (Wolvekamp & de Bruin, 1994) , and a sensitive colorimetric method for the assessment of serum DAO activity has been described (Takagi et al. 1994) . Plasma DAO activity has been reported to be low in a human subject with Cu de®ciency and to be able to differentiate between Cu-de®cient and Cu-adequate rats Kehoe et al. 2000) . The current study was conducted to investigate the response of several putative indices of Cu status, including serum DAO activity, to Cu supplementation in young men and women. Data emanating from the study should indicate the potential of these putative indices as indicators of sub-optimal Cu status in healthy populations.
Subjects and methods

Subjects and supplementation regime
Twenty-four healthy free-living subjects (twelve female and twelve male), aged 22±45 years, were recruited from the staff and student population of the University of Ulster to participate in the double-blind, placebo controlled crossover study. Reasons for exclusion included smokers, those on medication, vitamin or mineral supplements, and the presence of disease such as diabetes or hypertension. The study protocol was reviewed and approved by the Ethical Committee of the University of Ulster. The study consisted of three separate 6-week supplementation regimens of 3 mg CuSO 4 , 3 mg copper-glycine chelate (CuGC), and 6 mg CuGC/d, each separated by placebo periods of equal length. Habitual dietary information was collected from each subject by means of a diet history (Livingstone et al. 1992 ) by a trained investigator at the beginning and on completion of the study. The records were then analysed using food portion sizes (Crawley, 1992) and nutrient intake calculated using the computer package COMP-EAT (Nutrition Systems, London, UK). The subjects' pro®les, including age, BMI, and average Cu and energy intake at baseline and Cu and energy intake at the end of the study are shown in Table 1 .
Laboratory procedures
Blood samples were collected after an overnight fast by antecubital venepuncture into evacuated heparinized, citrated, and plain tubes from each subject at baseline (two samples, 2 weeks apart), and at the end of each separate supplementation or placebo period. Heparinized samples were centrifuged (1800 g, 15 min at 48C) and 200 ml plasma aliquots were stored at -808C until analyses for caeruloplasmin oxidase activity and caeruloplasmin protein concentrations. The remaining blood sample was diluted to the original blood volume with 0×01 M-PBS pH 7×3 and centrifuged (2000 g, 20 min at 258C). The buffy layer was then aspirated from the sample, added to cold saline and centrifuged (2000 g, 10 min at 258C), the supernatant discarded and the leucocyte pellet resuspended in 6 ml distilled H 2 O. A volume of 2 ml 3×4 % w/v NaCl (w/v) was added to the suspension, which was then centrifuged (2000 g, 10 min at 258C); this procedure was repeated three times. The resuspended pellet was divided into two, centrifuged (2000 g, 10 min at 258C), and then resuspended in 150 ml either 0×01 M-PBS buffer, pH 7×3 or 5 mM-PBS±EDTA buffer, pH 7×4, for leucocyte SOD and CCO determinations respectively. Leucocyte suspensions were stored at -808C until analysis. Erythrocytes obtained after the aspiration of the buffy layer were resuspended in the original blood volume with 0×9 % NaCl solution and washed three times by centrifugation (2000 g, 10 min at 258C). A 500 ml aliquot of washed erythrocytes was stored at -808C until analysis for haemoglobin (Hb), and for SOD and GPX activities. Citrated blood samples were centrifuged to remove the platelet-rich plasma (160 g, 20 min at 258C). This was further centrifuged to obtain the platelet pellet (730 g, 10 min at 258C). The pellet was resuspended to the original plasma volume with 5 mM-PBS±EDTA, pH 7×4, washed three times, and ®nally resuspended in 0×6 ml 5 mM-PBS±EDTA, pH 7×4. Analyses for CCO activity and protein concentrations were performed on the fresh platelet extractions. Serum samples were prepared by centrifuging clotted whole blood samples (2000 g, 15 min at 48C). These were stored at -808C until analysis. All frozen samples were analysed in batch and in duplicate within 10 months of completion of the study.
Protein concentrations were determined using the method of Bradford (1976) (Bio-Rad Laboratories, Herts., UK), with bovine serum albumin as standard. The determination of Hb concentrations was performed using the cyanmethaemoglobin method. Erythrocytes (40 ml) were diluted 152 C. A. Kehoe et al. The samples were left for 5 min at room temperature and the haemoglobin concentration was determined within 1 h, in g/dl, using a haemoglobinometer (Coulter Electronics Ltd). Plasma caeruloplasmin oxidase activity was determined by a modi®cation of the method by Henry et al. (1960) , using p-phenylenediamine dihydrochloride (Sigma Aldrich Co Ltd, Poole, Dorset, UK) as substrate and measuring the rate of oxidation of p-phenylenediamine dihydrochloride at 378C. Analysis was performed on the Cobas Fara automatic analyser (Roche, Basel, Switzerland). Caeruloplasmin protein concentrations were measured turbidimetrically using a modi®cation of the method of Calvin & Price (1986) . Using dilution buffer, pH 7×3, plasma was prediluted 1 : 41 (v/v) and mixed with excess rabbit anti-human caeruloplasmin (Dako, Glostrup, De nmark). The resulting antibody±antigen complex was stabilised with a phosphate buffer containing polyethylene glycol 6000 (BDH Ltd). The absorbance at 340 nm was measured on the Cobas Fara automatic analyser (Roche), and concentrations (U/l) were determined from a standard curve calculated using a human serum protein calibrator (Dako).
The activity of SOD was determined on the Cobas Fara automatic analyser (Roche) by a modi®cation of the method of Jones & Suttle (1981) , using a commercial kit, RANSOD. (Randox Laboratories, Co. Antrim, Northern Ireland). Activity of SOD was expressed per g Hb in erythrocytes, and per mg protein in leucocytes.
Erythrocyte GPX activity was assessed by a modi®cation of the method of Paglia & Valentine (1967) using a commercially available kit, RANSEL (Randox Laboratories). The assay was performed on the Cobas Fara automatic analyser (Roche). GPX activity was expressed as U/g Hb.
The assay for CCO activity (U/g protein) was performed on fresh platelet suspensions and leucocytes using a modi®cation of the method described by Smith (1955) . Immediately prior to running the assay, 0×2 ml of the platelet suspension was sonicated at an amplitude of 10 mm/6 s. The substrate cytochrome c (Sigma) was reconstituted in 0×1 M-K 2 PO 4 buffer, pH 7×0, and reduced with sodium dithionite (Sigma). The excess sodium dithionite was removed by separation using a G-25 Sephedex column (Pharmacia Biotech, Uppsala, Sweden), and the ®nal concentration was standardised at 57×7 mM (60×3 %) to ensure a concentration of 50 mM in the ®nal reaction mix. The CCO activity was determined on the Cobas Fara automatic analyser (Roche) by measuring the loss of ferrocytochrome c at 550 nm at 378C. A CCO (Sigma) buffered suspension, reconstituted in PBS buffer, was used as an in-house control for the CCO assay.
Serum DAO activity was determined on the Cobas Fara automatic analyser (Roche), using a modi®cation of the method described by Tagaki et al. (1994) . A substrate solution (36 mmol/l) was prepared by dissolving cadaverine dihydrochloride (Sigma) in a 25 mmol 1,4-piperazinediethane sulphonic acid (PIPES) buffer/l (pH 7×2). The substrate solution, 130 ml, was incubated at 378C for 5 min, after which 30 ml serum sample and 20 ml PIPES buffer were added, mixed and incubated for 30 min at 378C. The colour solution was prepared by dissolving 10 mmol DA-67 (Wako Chemicals USA, Inc., Richmond, VA, USA) in 100 ml 25 mmol 2-(N-morpholino)ethanesulfonic acid (MES) buffer/l (Sigma). Just before the addition of the colour solution to the assay, 6 U/ml peroxidase and 5 U/ml ascorbate oxidase (Sigma) were added to the colour solution. The development of methylene blue was initiated by the addition of 150 ml colour solution to the reaction mixture and the rate of colour development at 668 nm was measured over 12 min and quanti®ed (U/l) by a standard curve prepared using DAO (Sigma) standards.
Data analysis
All data were analysed using the SPSS 6.1 for Windows statistical package (SPSS Inc., Chiago, IL, USA) and performed at each crossover only on subjects who completed both supplementation and placebo regimens. The presence of carryover was tested for at each crossover as outlined by Senn (1993) . The effect of Cu treatment compared to placebo was analysed at each crossover by independent t tests of`period differences' between supplementation sequences, a method that adjusts data for any possible period effects. One-way ANOVA was used to examine differences between the sexes at baseline. Unavoidable absences of subjects at particular blood sampling times account for differences in crossover numbers.
Results
Women had signi®cantly higher plasma caeruloplasmin oxidase activity (725 (SE 59×1) U/l; P , 0×001), plasma caeruloplasmin protein concentration (0×24 (SE 0×2) g/l; P , 0×05), and serum DAO activity (0×24 (SE 0×29) U/l; P , 0×01) than men (552 (SE 44×4) U/l, 0×16 (SE 0×01) g/l and 0×10 (SE 0×13) U/l respectively) at baseline. Erythrocyte and leucocyte SOD, and erythrocyte GPX showed no changes in activity in the total group or in male and females separately after any Cu supplementation regimen (Table 2) . Platelet CCO activity was signi®cantly higher following supplementation with 6 mg CuGC than during the placebo regimen (P , 0×01) in the total group and in women but not in men (Table 2) . Signi®cant carryover effects were observed in platelet CCO activity in women during crossover with 3 mg CuGC (P , 0×05) and in leucocyte CCO activity in men during each crossover: 3 mg CuSO 4 (P , 0×05), 3 mg CuGC (P , 0×01), 6 mg CuGC (P , 0×05) ( Table 2 ). No signi®cant difference was observed in the response of plasma caeruloplasmin oxidase activity and caeruloplasmin protein concentration to any Cu supplementation regimen in the total group or in women. Men showed a signi®cant increase in plasma caeruloplasmin oxidase activity after supplementation with 3 mg CuSO 4 (P , 0×05), and plasma caeruloplasmin concentration was signi®cantly decreased after supplementation with 6 mg CuGC (P , 0×05). Serum DAO activity increased signi®cantly during all three Cu-supplementation regimens. This increase was observed in the total group and in both men and women separately (P , 0×01) ( Table 2) .
Discussion
The ®ndings from the current study indicate that serum DAO activity shows a marked response to Cu supplementation in healthy subjects. This increase in DAO activity was evident in both men and women and after each Cu-supplementation period. These results suggest that serum DAO activity is responsive to Cu intake and has the potential to be a sensitive indicator of Cu status in human subjects.
Serum DAO activity, however, is raised in pregnancy (Kusche et al. 1974) , uraemia (Tam et al. 1979) , kidneydialysis patients and after gastrointestinal damage (Wolvekamp & deBruin, 1994) , and is reportedly lowered in Crohn's disease and coeliac disease (Bayless et al. 1981) . Tagaki et al. (1994) have questioned the signi®cance of lowered serum DAO activity in these latter diseases as basal activity of serum DAO is very low in normal healthy individuals. We also found very low serum DAO activity in our subjects at baseline and at the end of the placebo periods. It is possible, therefore, that the rise in serum DAO activity after Cu supplementation is simply re¯ecting alterations in gut integrity caused by ingestion of the supplement. Our subjects, however, did not report any adverse side effects during the study. Moreover, DiSilvestro et al. (1997) have found signi®cantly lower plasma DAO activity in Cu-de®cient rats and low plasma DAO activity in a woman with spontaneous Cu de®ciency who responded to parenteral Cu repletion by increases in plasma caeruloplasmin protein concentration and caeruloplasmin oxidase activity accompanied by an increase in plasma DAO activity. Data from our laboratory show that marginally Cu-de®cient rats have signi®cantly lower plasma DAO activity and liver Cu content but no differences in other indices of Cu status compared with Cu-adequate controls (Kehoe et al. 2000) . Taken together, these ®ndings imply that serum or plasma DAO activity can also respond to changes in Cu status as well as to alterations in intestinal structural integrity. Serum DAO activity was higher in women than men at baseline. This Cu-metalloenzyme showed similar sex differences to the well-documented higher caeruloplasmin oxidase activity and protein concentrations in women compared with men (Fisher et al. 1990; Johnson et al. 1992; Milne & Johnson, 1993) . It is unlikely that the small increase observed in plasma caeruloplasmin activity after 3 mg CuGC or the small decrease in caeruloplasmin protein after 6 mg CuCG in our male subjects is of physiological signi®cance. No changes were noted in plasma caeruloplasmin protein concentrations in sixteen healthy infants after supplementation with 9×1 mmol Cu/d for the ®rst year of life (Salmenpera et al. 1989) and in seven adults receiving 10 mg Cugluconate for 12 weeks (Pratt et al. 1985) . In contrast to the present study, in a similar placebo-controlled intervention, increases in serum caeruloplasmin protein concentration were observed in eight healthy male subjects after supplementation with Cu-gluconate (2 mg Cu/d) for 6 weeks (Medeiros et al. 1991) .
The signi®cant increase in platelet CCO activity (only after 6 mg/d CuGC supplementation) seen in our subjects, and which was largely driven by increased activity in women, is apparently at variance with the reported sensitivity of this enzyme as an indicator of Cu status based on depletion studies in women (Milne & Forrest, 1996) , and men (Turnlund et al. 1997) where both mononucleated cell and platelet CCO activities were analysed. The signi®cant carryover that was observed in several of the crossover regimens in the current study with this index, however, is a major confounding problem. In the absence of any effective method of adjusting data for carryover, this phenomenon can only be noted (Senn, 1993) , and limits the interpretation of results of CCO activity, as the carryover effect may mask a possible treatment effect in the current study.
The responses of Cu-metalloenzymes, such as erythrocyte SOD activity, appear to be sensitive indicators of changes in Cu status in depletion studies (Milne & Forrest, 1996; Turnlund et al. 1997 ), but do not seem to respond to supplementation in healthy subjects. For example, Medeiros et al. (1991) found no signi®cant difference in SOD activity of men supplemented with 3 mg Cu-gluconate/d for 6 weeks when compared to controls. Our observation that supplementation with different Cu compounds and at different Cu concentrations did not alter SOD activity is in agreement with these ®ndings. It should be noted that mean dietary Cu intakes in our study were 1×38±1×59 mg/d for men and 1×08±0×98 mg/d for women and supplementation with 6 mg CuGC would increase intakes of Cu to greater amounts than those usually reported in western diets (Klevay et al. 1993) .
In conclusion, the results of our study indicate that serum DAO activity increases after Cu supplementation in both healthy men and women and has the potential to be a sensitive functional indicator of Cu status in human subjects. As serum DAO activity has not been investigated extensively as an indicator of Cu status, future experimentation should further elucidate the speci®city of the enzyme to changes in Cu status and the health consequences, if any, of low serum DAO activity.
